News & Events

 

Tessa Therapeutics completes USD 80 million funding round

 
Tessa Therapeutics completes USD 80 million funding round

21 December 2017

Congratulations to our client Tessa Therapeutics who have announced the successful completion of a USD 80 million funding round led by Temasek, an investment company headquartered in Singapore.

Tessa Therapeutics are an international clinical stage biopharmaceutical company that focus on T cell therapy for solid tumours. The proceeds from this funding round will be used to further advance its clinical pipeline and bring new therapies, based on the Virus Specific T cell (VST) platform, into clinical trials.

Read the full press release.

Our life sciences patent team work with Tessa Therapeutics on their IP portfolio. The team includes Partners Richard Clegg and Frances Salisbury, Associate Adam Gregory and Technical Assistant Anna Mudge.